Genetics of primary macronodular adrenal hyperplasia

Maria Candida Barisson Villares Fragoso¹,², Guilherme Asmar Alencar³, Antonio Marcondes Lerario², Isabelle Bourdeau³, Madson Queiroz Almeida¹,², Berenice Bilharinho Mendonca¹ and André Lacroix³

¹Unidade de Suprarrenal, Disciplina de Endocrinologia e Metabologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
²Instituto do Câncer de São Paulo ICESSP, São Paulo, Brazil
³Département de Médecine, Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada

Abstract

ACTH-independent macronodular adrenal hyperplasia is a rare cause of Cushing’s syndrome (CS), accounting for <2% of all endogenous CS cases; however it is more frequently identified incidentally with sub-clinical cortisol secretion. Recently, cortisol secretion has been shown to be regulated by ectopic corticotropin, which is in turn produced by clusters of steroidogenic cells of the hyperplastic adrenal nodules. Hence, the term ‘ACTH-independent’ is not entirely appropriate for this disorder. Accordingly, the disease is designated primary macronodular adrenal hyperplasia (PMAH) in this review article. The means by which cortisol production is regulated in PMAH despite the suppressed levels of ACTH of pituitary origin is exceedingly complex. Several molecular events have been proposed to explain the enhanced cortisol secretion, increased cell proliferation, and nodule formation in PMAH. Nonetheless, the precise sequence of events and the molecular mechanisms underlying this condition remain unclear. The purpose of this review is therefore to present new insights on the molecular and genetic profile of PMAH pathophysiology, and to discuss the implications for disease progression.

Key Words

- adrenal cortex
- adrenal hormones
- molecular genetics
- mutations
- gene expression

Introduction

Adrenocorticotropic hormone (ACTH)-independent macronodular adrenal hyperplasia (AIMAH) is a rare and insidious cause of Cushing’s syndrome (CS), and accounts for <2% of all endogenous cases of CS (Arnaldi et al. 2003, Lacroix & Bourdeau 2005, Newell-Price et al. 2006, Nieman et al. 2008). AIMAH is a heterogeneous disease that has received different names since its original description by Kirschner et al. (1964). Recently, it has been shown that AIMAH is not truly corticotropin-independent, because the regulation of cortisol secretion is exerted in part by ectopic production of corticotropin by clusters of adrenal cells, which in turn can be modulated by aberrant G protein-coupled membrane receptors (Louiset et al. 2013) to stimulate cortisol production. Based on these data, the authors suggested a designation of the disease as bilateral macronodular adrenal hyperplasia (BMAH; Lacroix 2013, Louiset et al. 2013). Alencar et al. (2014) described a large Brazilian family with AIMAH, in which the affected members showed distinct disease patterns on a patient-by-patient basis (i.e. bilateral vs unilateral adrenal macronodules). For these reasons, we hereafter refer to the disorder as primary macronodular adrenal hyperplasia (PMAH; Fig. 1) instead of AIMAH or BMAH.
PMAH is usually characterized by functioning adrenal macronodules and variable cortisol secretion, and is generally identified as incidental bilateral adrenal hyperplasia in radiological images or during the evaluation of CS (Hsiao et al. 2009, Lacroix 2009). However, the asymmetric/asynchronous involvement of only one adrenal gland can also occur in PMAH (Alencar et al. 2014), making disease diagnosis a challenge. Subclinical CS is the most common clinical manifestation of PMAH, whereas classical CS is observed during the fifth and sixth decades of life, corresponding to a later age of onset than other types of CS (Lacroix & Bourdeau 2005, Newell-Price et al. 2006, Lacroix 2009). Reports of familial clustering have been described in the last several years, suggesting that familial PMAH may be inherited in an autosomal dominant manner (Findlay et al. 1993, Minami et al. 1996, Imohl et al. 2002, Miyamura et al. 2002, Nies et al. 2002, Lee et al. 2005, Vezzosi et al. 2007, Watson et al. 2007, Gagliardi et al. 2009, Alencar et al. 2014). However, the sporadic form of PMAH (i.e. not associated with any stimulus of abnormal receptor. The activation of this pathway leads to phosphorylation of a number of transcription factors (TFs), culminating in the expression of steroidogenic enzymes during cortisol synthesis in the adrenal glands, as well as hyperplasia. The inactivating mutations of ARMCS prevent its pro-apoptotic function probably involved in adrenal hyperplasia; however, this mechanism is unclear. MC2R, melanocortin 2 receptor; CYP11A1, cholesterol desmolase; CYP11B1, 11β-hydroxylase; CYP17, 17α-hydroxylase; CYP21A2, 21-hydroxylase; DAG, diacylglycerol; IP3, inositol triphosphate; M, mitochondria; N, nucleus; PLC, phospholipase C; V1R, V1 vasopressin receptor; 3β-HSD, 3β-hydroxysteroid dehydrogenase; ARMCS, armadillo repeat-containing 5.

Figure 1
The main mechanism for PMAH development. The MC2R is a G protein-coupled receptor of the ACTH, expressed in adrenal zona fasciculata. Abnormal regulation of the adrenal cortex as mediated by aberrant hormone receptors. Various hormones, including gastric inhibitory peptide (GIP), epinephrine (E), norepinephrine (NE), luteinizing hormone (LH), human chorionic gonadotropin (hCG), serotonin, and vasopressin, can bind to their respective aberrant membrane receptors (ectopic or eutopic) coupled to assorted G proteins (Gs, Gi, and Gq), thereby determining the activation of adenyl cyclase (AC)-mediated signaling pathways by cAMP and protein kinase A (PKA). Ectopic ACTH acts on autocrine/paracrine regulatory mechanisms on MC2R to increase cortisol production after
family history or genetic defect) appeared to be most common; nevertheless, the actual prevalence of familial vs sporadic disease is unknown, because active research on the index case’s relatives was not a routine practice before the recent descriptions of a causative genetic factor for this disease (Assie et al. 2013, Alencar et al. 2014, Faucz et al. 2014, Gagliardi et al. 2014). Recent studies have now indicated that PMAH is more frequently genetically determined than previously believed (see section ‘Participation of a new gene, ARMCS, in PMAH’).

Molecular mechanisms involved in PMAH

Over the last two decades, different studies support that multiple molecular mechanisms may be involved in the pathogenesis of PMAH, suggesting that it may be a heterogeneous group of diseases that have a common presentation. In the following sections, we highlight the molecular abnormalities that have been proposed to be involved in PMAH pathogenesis (Fig. 1).

Activating mutations in the melanocortin 2 receptor gene

Under normal conditions, ACTH is the main regulator of cortisol and androgen synthesis in the adrenal cortex. ACTH exerts its actions through the melanocortin 2 receptor (MC2R), which belongs to the family of G protein-coupled receptors (GPCRs), also called seven transmembrane domain receptors. The cytoplasmic carboxy-terminal domain of MC2R interacts with various other protein receptors. In its inactivated state, the stimulatory G protein of MC2R is a heterotrimer formed by two alpha subunits (α) attached to a molecule of GDP, along with one beta subunit (β) and one gamma subunit (γ). Activation of the G protein involves the exchange of GDP for GTP.

The MC2R gene (Online Mendelian Inheritance in Man (OMIM) database number 607397) is located on chromosome 18p11.21. MC2R activation is the first step in the stimulation of the cAMP/protein kinase A (PKA) downstream signaling pathway, and every step in this pathway may be affected by the activation of MC2R. So far, only two patients with activating MC2R mutations have been identified, and only one of these patients was diagnosed with PMAH. Swords et al. (2002) performed an in vitro functional study demonstrating that the p.Phe278Cys MC2R mutation, previously described as homozygous in a patient with PMAH, determined the increase in MC2R protein basal activity/cAMP elevation and inhibited MC2R desensitization/internalization.

In another in vitro functional study, mutations at two concomitant receptor sites (p.Cys21Arg and p.Ser247Gly) constitutively activated the MC2R. These latter mutations occurred in the same allele in a patient with known hypersensitivity to ACTH (Hiroy et al. 1998, Swords et al. 2004). In both of the above patients, germline MC2R mutations were also found.

The hypothesis that an activating MC2R mutation could lead to constitutive activation of the downstream cAMP/PKA signaling pathway and the consequent autonomy of the adrenal gland was previously investigated (Latronico et al. 1995, Swords et al. 2002). However, later studies have shown that this is an extremely rare causative factor of PMAH (Fragoso et al. 2003, Alencar et al. 2014).

Abnormal regulation of the adrenal cortex by aberrant hormone receptors

The concept of abnormal hormone receptors in the adrenal gland was first proposed in 1971, by Schorr & Ney (1971). These investigators conducted an in vitro analysis with primary cells derived from a transplantable rat adrenal carcinoma and showed that corticosterone was produced in response to three adenylate cyclase-activating agents: ACTH, catecholamine, and thyroid-stimulating hormone. Subsequent in vitro studies demonstrated functional coupling of membrane receptors for additional hormones in adrenocortical adenomas/carcinomas in higher animals, including humans (Lacroix et al. 2001, Antonini et al. 2004). Hamet et al. (1987) described the case of a patient with CS secondary to an adrenal adenoma, who presented with cortisol synthesis associated with food intake. From this point onward, the concept of aberrant hormone receptors began to gain clinical significance.

Some years later, two independent research groups demonstrated normal cortisol production in association with oral food intake in some subjects with PMAH (Lacroix et al. 1992, Reznik et al. 1992). In these PMAH patients, the hypercortisolism was triggered by the gastrointestinal hormone, gastric inhibitory peptide or glucose-dependent insulinotropic peptide (GIP). Since then, a high proportion of PMAH cases and a lesser proportion of adrenal adenoma cases have been documented, in which the patients presented cortisol release stimulated by hormones other than pituitary–ACTH (Lacroix et al. 1993, 2010, Christopoulos et al. 2004). However, it is not entirely clear whether the expression of these receptors is primarily responsible for PMAH pathogenesis, or is merely
a secondary phenomenon resulting from cell proliferation state and dedifferentiation. In addition, no genetic abnormalities have been found in the coding or promoter regions of aberrant hormone receptor genes.

Some investigations support the aberrant expression of G-protein receptors as an initial and essential event in the pathogenesis of PMAH (Lacroix et al. 2004). Consistent with this hypothesis, aberrant receptors are almost universally present in PMAH, and even at the early stages of the disease (Bertherat et al. 2005, Libe et al. 2010). Furthermore, PMAH-like steroidogenesis can take place in vitro after hormone stimulation (Bertherat et al. 2005). Moreover, the temporal relationship between documented hypercortisolism and high levels of luteinizing hormone (LH)/human chorionic gonadotropin (hCG) during pregnancy and menopause in certain patients, and transfection experiments of GIP or the LH/hCG receptor into the adrenal cells of animal hosts, convincingly support a connection between gland hyperplasia and hypercortisolism in vivo (Lacroix et al. 1999, Mazzuco et al. 2006a,b).

On the other hand, it is possible that the presence of aberrant receptors is a secondary event resulting from cell proliferation and dedifferentiation rather than a decisive causative factor (Bourdeau & Stratakis 2002). Supporting this idea is the fact that the in vivo inhibition of specific aberrant receptors using β-adrenergic antagonists or suppression of endogenous LH using leuprolide acetate: these therapies were able to control the hypercortisolism, but have never reduced the size of the macronodular adrenal hyperplasia (Lacroix et al. 1999, Feelders et al. 2003). Moreover, Swords et al. (2005) demonstrated that increased expression of an aberrant GIP receptor can also present in adrenal hyperplasia secondary to ACTH-dependent CS and that cultured adrenal cells derived from affected patients respond to in vitro stimulation with GIP, suggesting that chronic adrenal stimulation with ACTH and constitutive activation of the MC2R downstream signaling pathway may induce aberrant expression of the GIP receptor. However, these findings were not confirmed by Antonini et al. (2006), who failed to demonstrate significant expression of GIP receptor in patients with chronic Cushing’s disease undergoing bilateral adrenalectomy. Therefore, the role of the aberrant expression of GIP receptor as a causative factor of PMAH remains unclear.

Starting with the assumption that aberrant hormone receptors play a key role in the initiation and progression of PMAH, one might expect that the affected individuals belonging to the same family would express the same type of aberrant receptors. In certain families, specific aberrant GPCR including vasopressin, β-adrenergic, and SHT4 receptors were found in all members of patients affected with PMAH (Miyamura et al. 2002, Lee et al. 2005, Vezzosi et al. 2007). In contrast, this was not found in members of the largest known family with PMAH, residing in Brazil (Alencar et al. 2014). Interestingly, cortisol production in response to assorted stimuli showed a lack of uniformity in the family members, despite their common pedigree. Furthermore, the intensity and frequency of patient responses were not related to the size or number of adrenal nodules in each affected individual, or to the degree of prior hypercortisolism (Alencar et al. 2014).

Heterozygous gsp point mutations

The gene encoding the alpha subunit of stimulatory G proteins (GNAS, OMIM 139320) is located on chromosome 20q13.32 (Weinstein et al. 2004). McCune–Albright syndrome (MAS) is caused by post-zygotic (somatic) activating mutations in this gene. These heterozygous point mutations are also termed gsp mutations and determine the loss of intrinsic GTPase activity of the alpha subunit, with subsequent constitutive activation of adenylate cyclase (Antonini et al. 2004, Brown et al. 2010).

Clinical manifestations of MAS are variable and depend mainly on the distribution of somatic mosaic mutations in the affected tissues. The syndrome presents with a classic triad of polyostotic fibrous dysplasia, ‘café au lait’ skin spots, and isosexual, gonadotropin-independent precocious puberty (Brown et al. 2010). Clinical variations on the classic triad can occur together with other endocrine and non-endocrine abnormalities. Bilateral adrenal hyperplasia and CS may accompany MAS, in young children with MAS, but this is not common and is characterized by adrenal nodules carrying the gsp mutation and internodular atrophy of nonaffected adrenal cortex (Weinstein et al. 2004, Brown et al. 2010).

Fragoso et al. (2003) identified two distinct gsp somatic mutations affecting arginine residues in codon 201 of GNAS in few patients with PMAH, but the patients had no other typical manifestations of MAS. Subsequently, Hsiao et al. (2009) reported gsp somatic mutation in one additional patient with PMAH. Such cases might represent variations of MAS. Alternatively, they might characterize late gsp somatic mutations, given that similar mutations have been described outside the context of MAS (e.g. together with acromegaly, thyroid cancer, and ovarian
and testicular neoplasms; Antonini et al. 2004, Hsiao et al. 2009). On the other hand, an additional study failed to observe gsp mutations in PMAH (Christopoulos et al. 2005). Possibly, technical variations in the methodologies employed for the investigation of gsp mutations could explain the discrepancy in these published findings.

Based on strong previous evidence implying that increased cAMP signaling is sufficient for cell proliferation and cortisol production, we surmise that these somatic activating mutations in GNAS are probably sufficient for macronodule formation and the hypercortisolism status (Lania et al. 2006, Meoli et al. 2008, de Joussineau et al. 2012).

**Association between PMAH and multiple endocrine neoplasia type 1**

Multiple endocrine neoplasia type 1 (MEN1) is a complex genetic syndrome caused by mutation in the tumor suppressor gene, *MEN1* (OMIM 613733), which is located on chromosome 11q13.1. The MEN1 gene product is a protein called menin, which directly interacts with DNA and a number of other proteins and transcription factors (TFs). In this way, menin directly and indirectly regulates the cell cycle; inhibits cell proliferation; participates in DNA repair; interacts with the JunD proto-oncogene to inhibit its transcriptional activity and consequently cell growth; and performs various additional functions not listed here (Balogh et al. 2006). The MEN1 gene is transmitted in an autosomal dominant fashion and shows variable expression with age. The ensuing genetic syndrome is typified by its association with hyperparathyroidism, pituitary adenomas, and pancreatic islet tumors. Other manifestations may also be present and encompass adrenocortical lesions, lipomas, facial angiofibromas, collagenomas, duodenal gastrinomas, thyroid tumors, carcinoïd tumors, and meningiomas (Thakker 2010, Newey & Thakker 2011).

Adrenocortical lesions are relatively frequent in MEN1, and bilateral enlargement of the adrenal glands is documented in up to 21% of patients (Skogseid et al. 1992, Lacroix & Bourdeau 2005). The pathophysiology of adrenocortical changes in MEN1 is not yet understood. According to a model proposed by Knudson for tumor development (Knudson’s two-hit model), the initially unmutated MEN1 allele might be expected to generate a somatic inactivation in the hyperplastic adrenal gland; however, this apparently is not the case. Unlike other tumors associated with MEN1, loss of heterozygosity (LOH) has not been demonstrated among adrenocortical lesions (Skogseid et al. 1992, Costa et al. 2011). Furthermore, somatic or germline mutations are not found in MEN1 patients in the absence of concomitant PMAH. Some cases of PMAH with CS were found to have MEN1 or MEN1-like syndrome (hyperparathyroidism, insulinomas, and/or pituitary tumors) with or without MEN1 mutations (Sato et al. 2006, Lee et al. 2011, Yoshida et al. 2011).

**Association between PMAH and familial adenomatous polyposis coli**

Familial adenomatous polyposis coli (APC) is an inherited autosomal dominant condition linked to an inactivating germline mutation of the tumor suppressor gene, *APC* (OMIM 617361), located on chromosome 5q22.2 (Jang et al. 2010). The APC protein has multiple domains, through which it interacts with a host of other proteins, including β-catenin, axin, and microtubule-associated proteins. Through these interactions, APC exerts numerous activities, including inhibition of the canonical Wnt signaling pathway, control of cell proliferation and differentiation, regulation of cell adhesion and migration, and stabilization of chromosome segregation (Aoki & Taketo 2007).

The bi-allelic inactivation of APC results in the constitutive activation of β-catenin and consequently the canonical Wnt signaling pathway, predisposing patients to tumorigenesis (Berthon et al. 2012). Familial APC is characterized by numerous adenomatous polyps in the colon and the rectum, beginning at the second and third decade and continuing throughout life. Colorectal carcinomas develop with progression of the disease, and have an incidence of nearly 100% after 40 years in the absence of adequate treatment (Groen et al. 2008, Hosogi et al. 2009). Certain intestinal manifestations occur more frequently in individuals with familial APC, such as papillary thyroid carcinomas, hepatoblastomas, brain tumors, pancreatic carcinomas, adrenocortical lesions, desmoid tumors, osteomas, epidermoid cysts, fibromas, lipomas, and congenital hypertrophy of the retinal pigment epithelium (Gaujoux et al. 2010).

Adrenocortical lesions (adenomas, carcinomas, and PMAH) occur two to four times more frequently in patients with familial adenomatous polyposis than in normal controls (Groen et al. 2008, Berthon et al. 2012). These lesions usually reveal a bi-allelic inactivation of APC, namely, the presence of germinal and somatic mutations in adrenal tissue, in accordance with the
proposed Knudson model (Blaker et al. 2004, Hosogi et al. 2009, Gaujoux et al. 2010, Berthon et al. 2012). In a previous study, only one patient with familial adenomatous polyposis and PMAH failed to display LOH of APC in adrenal hyperplasia (Yamakita et al. 1997). Ample experimental evidence, including that provided by animal models, has indicated that canonical Wnt signaling participates in adrenal tumorigenesis. Therefore, this same signaling pathway might factor in the pathophysiology of PMAH (Berthon et al. 2012). So far, germline and somatic mutations in the APC gene have been only described in the context of PMAH associated with familial adenomatous polyposis (Hsiao et al. 2009).

Association between PMAH and hereditary leiomyomatosis and renal cell carcinoma

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant genetic syndrome caused by inactivating mutations of the tumor suppressor gene, fumarate hydratase (FH or OMIM 136850), found on chromosome 1q43 (Sudarshan et al. 2007). This gene encodes an enzyme that converts fumarate to malate in the tricarboxylic acid cycle (also known as the Krebs cycle). With the inactivation of FH, fumarate accumulates inside the mitochondria. The excess substrate overflows into the cytoplasm, inhibiting a group of prolyl hydroxylases. Inhibition of these enzymes determines the activation status of a TF termed hypoxia-induced factor 1 (HIF1), favoring increased glycolytic activity, neovascularization, and downregulation of cellular apoptosis, all important features of tumorigenesis (King et al. 2006, Badeloe & Frank 2009).

HLRCC is characterized by cutaneous leiomyomas, leiomyosarcomas, uterine leiomyomas, and papillary renal carcinomas (Matyakhina et al. 2005). Bi-allelic inactivation of the FH gene generally accompanies this tumor-associated genetic syndrome, along with loss of the normal allele. Bilateral adrenal lesions are occasionally observed in isolated cases of HLRCC (Matyakhina et al. 2005, Lehtonen et al. 2006). In one of these cases, the bilateral lesions accompanied LOH of the FH gene in the hyperplastic adrenal gland (Matyakhina et al. 2005). Recently, four bilateral adrenal lesions have been found among 255 cases of HLRCC (Shuch et al. 2013).

There are few reports to date of mutations in the FH gene, and PMAH in affected individuals occurred only within the context of HLRCC (Hsiao et al. 2009). Although a fortuitous relationship cannot be excluded, HLRCC may be added to the list of monogenic disorders reportedly associated with the development of hyperplastic adrenal nodules. Thus, FH may be considered as a candidate gene for heterogeneous PMAH (Matyakhina et al. 2005).

Signaling pathways and genetic alterations potentially related to PMAH

Several studies have analyzed gene expression in AIMAH/PMAH so as to investigate prospective signaling pathways and potentially disease-related molecular mediators.

Bourdeau et al. (2004) evaluated the gene expression profile in PMAH by conducting a microarray analysis of cDNA derived from adrenal tissue samples of eight patients with the disorder. The investigators paid particular attention to the activation of signaling pathways downstream of HIFs and Wnt, in addition to the aberrant expression of the GIP receptor. Notably, previous work showed that HIF- and Wnt-mediated pathways are hyperactivated in two distinct genetic syndromes related to PMAH: HLRCC and familial adenomatous polyposis respectively (Aoki & Taketo 2007, Sudarshan et al. 2007). According to the results of Bourdeau et al. (2004), the PKA signaling pathway might also be altered in PMAH, as it is in primary pigmented nodular adrenocortical disease (PPNAD; Bourdeau et al. 2004). Furthermore, Bourdeau et al. (2004) found that selected genes encoding steroidogenic enzymes were underexpressed in PMAH patients, strengthening the hypothesis of inefficient PMAH steroidogenesis.

In another investigation consisting of eight patients with AIMAH/PMAH and aberrant expression of the GIP receptor, Antonini et al. (2006) further examined the expression of several genes related to steroidogenesis and PKA signaling. Similar to the work of others, this study revealed paradoxical underexpression rather than overexpression of steroidogenesis-related genes. In this study, the PKA signaling pathway also appeared to be hypoactivated (Bourdeau et al. 2004).

Lampron et al. (2006) conducted a study of gene expression on a genome-wide scale (i.e. whole-genome expression profiling) involving five patients with PMAH and aberrant expression of the GIP receptor, and five patients with ACTH-dependent adrenal hyperplasia. The genetic material was extracted directly from each patient’s hyperplastic adrenal gland. Among the patients with PMAH, hypoexpression of genes related to steroidogenesis was again demonstrated. A French research group also observed abnormal gene overexpression of several not yet described transmembrane GPCRs in a number of PMAH
subjects (Assie et al. 2010). Despite these findings, hypo/hyperexpression of genes has not been convincingly and directly linked with the main cAMP/PKA signaling pathway potentially related to PMAH.

Bourdeau et al. (2006) conducted a further study with the aim of specifically assessing whether the PKA signaling pathway was altered in PMAH. Although no mutations were found in the regulatory subunit of PKA type 1A (PRKAR1A) gene, which is often described as mutated in PPNAD and the Carney complex gene (Stratakis & Boikos 2007), PKA activity was higher in PMAH compared with normal adrenal glands. Based on their findings, the investigators proposed that altered expression of the PKA regulatory subunits might lead to increased kinase activity.

**Additional whole-genome expression profiling in PMAH**

In another whole-genome expression profiling study, Almeida et al. (2011) evaluated different details of adrenal nodules from the same patient with PMAH. Gene expression was analyzed in each adrenal nodule on a genome-wide scale, and chromosomal disorders were assessed by comparative genomic hybridization microarray analysis with relevant oligonucleotides. Regions of chromosomal gain occurred more frequently in major adrenal nodules, with more than half of the overexpressed, amplified genes located in such portions of the genome. The expression pattern of some genes also suggested the activation of Wnt signaling, in agreement with the previously discussed findings of Bourdeau et al. (2004).

Recent studies have demonstrated the role of Wnt signaling in the development of adrenal hyperplasia and adrenal tumor (Almeida et al. 2012, Berthon et al. 2012). Almeida et al. (2011) also reported that, although the genes of the catalytic subunits of PKA are overexpressed, enzyme activity tended to be lower in larger vs smaller nodules. Furthermore, the authors suggested that the increased size of the adrenal nodules was related to the progressive accumulation of chromosomal alterations and the activation of signaling pathways usually involved in tumorigenesis.

Gagliardi et al. (2012) conducted a study to evaluate genome-wide expression profiles in individuals with familial PMAH. Transcriptomes obtained from the adrenal glands of three affected brothers were compared with those obtained from the normal glands of two unaffected brothers. Unlike in previous investigations, this study revealed no significant hypoxpression of genes encoding steroidogenic enzymes. The authors initially observed an increase in cortisol levels in the three PMAH subjects after *in vivo* stimulation with vasopressin. Moreover, the receptor genes of arginine vasopressin were hyper-expressed in the hyperplastic adrenal glands. However, it was not possible to identify those genes related to aberrant expression of pertinent receptors or the associated mechanisms, and contrary to the expected results, the signaling pathways of the arginine vasopressin receptor were not hyperexpressed.

Finally, Gagliardi et al. (2012) showed that some of the genes differentially expressed in familial PMAH were previously linked with tumorigenesis. Thus, PMAH and malignant adrenocortical tumors apparently share certain signaling pathways, as previously proposed by Almeida et al. (2011).

Assie et al. (2010) employed cDNA microarray analysis to evaluate the whole-genome expression of more than 800 transmembrane GPCRs in a group of 18 patients with PMAH. The authors demonstrated the expression of several transmembrane receptors in hyperplastic adrenal glands not previously described in PMAH. In addition, several hyperplastic glands expressed receptors with a distinct frequency not observed in normal glands. Thus, it was difficult to assign the presence of a specific hormone receptor to hyperplasia. In this same study, the adrenal glands of CS patients also sometimes expressed GPCRs, even when chronically stimulated by ACTH. This latter finding, in a way, supports the hypothesis that aberrant expression of receptors in PMAH may be an epiphenomenon of disease pathophysiology.

**MicroRNA profile of PMAH**

MicroRNAs (miRNAs) are RNA molecules composed of about 22 nucleotides directed against protein coding and noncoding regions that act as potent post-transcriptional regulators of gene expression under physiological as well as pathological conditions. miRNAs bind to specific regions of mRNA, thereby promoting mRNA degradation and/or inhibiting protein translation (Ricarte Filho & Kimura 2006, Pritchard et al. 2012). Bimpaki et al. (2010) conducted a study of miRNAs in ten patients with PMAH, aiming to define the miRNA profile of the disease. Thirty-seven miRNAs with altered expression (low or high) were identified in the hyperplastic adrenal gland of PMAH patients. Two of these miRNAs especially caught our attention: miR-210 (with increased expression) and miR-200b (with reduced expression). miR-2010 transcription is stimulated by the HIF-mediated signaling cascade, while miR-200b acts as a regulator of matrin 3 protein translation, where matrin 3 is a nuclear matrix component.
and a substrate for PKA. Hence, miR-210 and miR-200b potentially play roles in PMAH development and/or progression.

Ectopic expression of corticotropin in PMAH

A few studies have been published over the last two decades, showing that affected adrenal glands display abnormal expression of ectopic corticotropin in PMAH. This implies that ectopic production of ACTH might induce adrenocortical hyperplasia and cortisol secretion (Pereira et al. 2001, Lefebvre et al. 2003, Mazzuco et al. 2007, Iwata et al. 2012).

A recent extensive study from Louiset et al. (2013) has revealed that the cortisol secretion by CS-associated adrenal hyperplastic macronodules was apparently regulated by ectopic ACTH. Ectopic ACTH was in turn produced by a cluster of steroidogenic adrenal cells acting in an autocrine/paracrine manner. The mRNA encoding the corticotropin precursor, pro-opiomelanocortin, was detected in all hyperplastic adrenal samples investigated. In addition, convertase type I expression was detected in adrenal cells, suggesting that the cells may generate bioactive corticotropin. Immunohistochemical staining confirmed the distribution of ACTH throughout the cells, and corticotropin secretion was observed at a higher concentration in adrenal vs peripheral veins from two patients with PMAH.

Louiset et al. (2013) examined the effects of classic regulators of pituitary ACTH secretion on the release of ectopic corticotropin by hyperplastic explants, but failed to uncover any significant action of the regulators. Interestingly, the release of adrenal corticotropin was stimulated by ligands of aberrant membrane receptors expressed by hyperplastic tissues (i.e. GIP, serotonin, and hCG). The corticotropin-receptor antagonists, corticostatin, and corticotropin 7–38 inhibited cortisol secretion by 40% in tissues that contained aberrant GPCRs. Thus, in vitro evidence supports the hypothesis that cortisol production is controlled by aberrant hormone receptors and ectopic corticotropin produced within adrenocortical tissue (Louiset et al. 2013). The concept of aberrant GPCR regulating autocrine ACTH production is also supported by the in vivo observation that in patients with GIP-dependent PMAH, cortisol levels can be low during fasting in the morning when circulating GIP is low and ACTH either from pituitary or from hyperplastic adrenal tissues is low (Lacroix et al. 2009). ACTH production appears to be present in PMAH tissues irrespective of the presence of armadillo repeat-containing protein 5 (ARMC5) mutation (see later).

Additional work indicated that PMAH tissues also produce serotonin, vasopressin, glucagon, and other factors that further contribute to the paracrine regulatory loops of cortisol secretion and cell proliferation (Lefebvre et al. 2013). These findings bolster the proposal that paracrine adrenal production of ACTH is central to the cortisol-facilitated regulation of PMAH. Preclinical and clinical studies are therefore required to examine whether novel drugs directed against the ACTH receptor (MC2R) can reverse excessive cortisol secretion in affected patients (Lacroix 2013).

Participation of a new gene, ARMC5, in PMAH

ARMC5 makes part of a large family of proteins, characterized by the presence of tandem repeats of an amino acid motif. This family is highly conserved through evolution in eukaryotic organisms (from yeast to human). β-catenin is a member of the armadillo protein family, and is known to be involved in adrenocortical development and adrenal disorders, such as adenomas and carcinomas (Hubert et al. 1997, Tewari et al. 2010).

The most important recent finding in this field is the discovery of germline mutations of ARMC5 in ~50% of patients with apparently sporadic PMAH, and also in a large family with genetically transmitted PMAH (Assie et al. 2013, Alencar et al. 2014). Germline mutations in the ARMC5 gene have been later confirmed in apparent sporadic and familial PMAH cases in up to 50% of the individuals investigated (Alencar et al. 2014, Fauz et al. 2014, Gagliardi et al. 2014). These mutations were uncovered by using single-nucleotide polymorphism arrays, linkage analyses, and whole-exome sequencing. The ARMC5 gene is located on chromosome 16p11.2 and has an unknown function. A second (somatic) mutational event (either 16p LOH or a second somatic mutation in the coding region of the gene) was identified, suggesting that ARMC5 may be a tumor suppressor gene. Consistent with that, an in vitro study has demonstrated that ARMC5 transfection to the adrenocortical cancer cell line H295R induces apoptosis (Assie et al. 2013). ARMC5 has no apparent link to the cAMP pathway, but its inactivation decreases the expression of both MC2R and various steroidogenic enzymes (Assie et al. 2013). Previous studies found that beyond a certain common event, such as ectopic expression of GIP receptors or germline ARMC5 mutations in diffuse hyperplasia, several somatic genetic events occurred in the different macronodules. Thus, the second somatic ARMC5 mutation or another second hit may contribute to the progression of macronodules.
However the function of ARMC5 remains unknown as do the mechanisms of the inactivating mutations of ARMC5 involved in development of adrenal macronodular hyperplasia (Berthon & Stratakis 2014).

Interestingly, six out of 11 (54%) first-degree relatives of seven probands carried a germline ARMC5 mutation; five of these showed at least one nodule on computed tomography (CT) scans, coupled with increased cortisol secretion in three cases (Alencar et al. 2014). One elderly patient (76 years of age) harboring a germline mutation did not show any abnormal hormonal results and showed a normal adrenal CT scan. It is possible that this patient did not have a second-hit ARMC5 molecular event in the adrenal gland, indicative of incomplete penetrance of PMAH (Alencar et al. 2014). Further familial studies will be useful to clarify the clinical penetrance of ARMC5 mutations.

The search for ARMC5 or other responsible genes should allow familial screening through a simple blood test, permitting the identification of at-risk individuals who would probably benefit from further evaluations (Assie et al. 2013, Lacroix 2013, Alencar et al. 2014).

Other molecular mechanisms of PMAH

Cao et al. (2014) investigated genetic lesions in adrenal CS by using whole-exome sequencing of DNA isolated from adrenocortical adenomas, PMAH lesions, and adrenocortical oncocytomas. The authors identified two novel mutations in the highly conserved methyltransferase domain of DOT1L, a histone H3 lysine 79 (H3K79) methyltransferase. DOT1L regulates transcription and cell proliferation, and also mediates cell transformation in mixed lineage-rearranged leukemia. In addition, the histone deacetylase gene HDAC9 was mutated in one PMAH case, while the affected individuals did not show either ARMC5 or GSP mutations. These data show that deregulated chromatin modifications might contribute to tumorigenesis in PMAH. Further investigations of these new mutations are required to elucidate their frequency and relevance in the molecular pathogenesis of PMAH.

Beuschlein et al. (2014) recently explored the constitutive activation of the PKA catalytic subunit in several forms of adrenal CS by using genome-wide copy-number analysis. The authors identified germline PRKACA gene duplications in a mother–son set of affected individuals with mild CS due to PMAH. The adrenal tissue of the subjects with PRKACA duplications exhibited higher PKA C alpha mRNA and protein levels in comparison with tumor tissue samples from patients without any known genetic defect. In addition, immunohistochemical experiments confirmed the higher expression levels of the PKA C alpha subunit in the adrenal glands of PMAH subjects. The authors concluded that the genetic variants of the PKA catalytic subunit in both adrenal hyperplasia and adenomas of the adrenocortical cortex could lead to pituitary ACTH-independent CS. Interestingly, somatic GNAS mutations were recently identified in 5–17% of cortisol secreting adenomas. PKA catalytic subunit mutations in cortisol secreting adenomas were also confirmed by other group (Lee et al. 2011).

The association between meningioma and PMAH: is it a coincidence or a new syndrome?

Lee et al. (2005) described two siblings with PMAH and high expression of vasopressin V1b and V2 receptors in the adrenal glands. The authors also reported incidentally found parasaigittal meningioma in the right parieto–occipital region in one sibling and a mass of size 3.0×2.5 cm in the left anterior falx that was thought to be a meningioma in the other sibling.

In a preliminary investigation (Alencar et al. 2014), we have found typical images of intracranial meningiomas or a previous history of these tumors in 43% of the Brazilian family members (three out of seven evaluated patients) with germline ARMC5 mutations and PMAH. The meningioma occurred in patients with classical or subclinical CS (age ranged 26–53 years of age).

In contrast, meningiomas are incidentally diagnosed in only 0.9% of the general population after the fourth decade of life (Vernooij et al. 2007). Recently in Germany, in a member of a family with PMAH with intracranial meningothelial meningioma WHO grade I, a somatic frameshift mutation in ARMC5 (p.R502fs) was identified, corroborating that such mutations can be causative for the associated meningiomas (Elbelt et al. 2014). The ARMC5 gene is ubiquitously expressed in normal human tissues (http://www.genecards.org), further studies are needed to investigate the potential involvement of ARMC5 mutations with occurrence of other neoplasias (Lacroix 2013).

Discussion/summary

CS is a challenging disease that results from chronic exposure to excessive levels of circulating cortisol. PMAH was initially regarded as a sporadic disease, but familial autosomal dominant forms are now recognized. The genetic origin of PMAH is supported by the bilateral
nature (in most cases) of the adrenal tumors and the propensity of the disease to run in families.

Germline mutations in the ARMC5 gene have been documented in apparent sporadic and familial PMAH cases in >50% of the individuals investigated (Alencar et al. 2014, Faucz et al. 2014, Gagliardi et al. 2014). In functional work performed by Assie et al. (2013), ARMC5 was found to induce apoptosis in H295R adrenocortical carcinoma cells. In addition, ARMC5 gene inactivation was reportedly associated with a slow process of dedifferentiation in adrenocortical cells, concomitant with reduced expression of MC2R and steroidogenic enzymes. Of note, MC2R and steroidogenic enzymes are also frequently reduced in PMAH. The function of the ARMC5 protein is unknown, but these findings suggest that its gene belongs to the tumor suppressor family.

Also of note, adrenal cells in PMAH are relatively inefficient in terms of steroidogenesis, and a large adrenal size seems to be required to produce sufficient cortisol for the induction of clinical hypercortisolism.

Consideration of PMAH as a pituitary corticotropin-independent variant of CS has highlighted the aberrant expression of ACTH in cell clusters obtained from hyperplastic adrenal tissues. Furthermore, the release of ACTH is triggered by ligands of aberrant membrane receptors. Interestingly, intra-adrenal corticotropin apparently stimulates cortisol secretion through a complex autocrine/paracrine mechanism involving MC2R, suggesting that intra-adrenal ACTH participates in the pathogenesis of hypercortisolism. In addition, the confirmation of somatic ARMC5 mutation in meningioma tissue from a patient with PMAH suggests an additional role for this gene.

Conclusions

Recent molecular genetic investigations of PMAH provide new insights for future research on adrenal disorders. The identification of a genetic basis for PMAH is anticipated to permit earlier diagnosis and to improve the management of this disease. An international, collaborative task force would substantially facilitate the study of large patient cohorts with this familial disease, including appropriate follow-up and therapy for such individuals with this heterogeneous adrenal disease.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.


Hsiao HP, Kirschner LS, Bourdeau I, Keil MF, Boikos SA, Verma S, Robinson-White AJ, Nesterova M, Lacroix A & Stratakis CA 2009 Clinical and genetic heterogeneity, overlap with other tumour syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-


Received in final form 27 October 2014

Accepted 29 October 2014